作者: Bart Vanhaesebroeck , Len Stephens , Phillip Hawkins
DOI: 10.1038/NRM3290
关键词:
摘要: Over the past two decades, our understanding of phospoinositide 3-kinases (PI3Ks) has progressed from identification an enzymatic activity associated with growth factors, GPCRs and certain oncogene products to a disease target in cancer inflammation, PI3K inhibitors currently clinical trials. Elucidation PI3K-dependent networks led discovery phosphoinositide-binding PH, PX FYVE domains as conduits intracellular lipid signalling, determination molecular function tumour suppressor PTEN AKT mTOR protein kinases key regulators cell growth. Here we look back at main discoveries that shaped field.